• Chemistry graduate student Elizabeth McCoy, left, and Sarah O'Connor, assistant professor of chemistry, inspect their latest batch of periwinkle root. They are working with periwinkle seedlings to produce potential new drugs.

    Chemistry graduate student Elizabeth McCoy, left, and Sarah O'Connor, assistant professor of chemistry, inspect their latest batch of periwinkle root. They are working with periwinkle seedlings to produce potential new drugs.

    Photo / Donna Coveney

    Full Screen
  • Catharanthus roseus

    Catharanthus roseus

    Photo / © P. Schönfelder

    Full Screen

Periwinkle can serve as tiny chemical plant

Chemistry graduate student Elizabeth McCoy, left, and Sarah O'Connor, assistant professor of chemistry, inspect their latest batch of periwinkle root. They are working with periwinkle seedlings to produce potential new drugs.


Some of nature's most complicated chemistry takes place in the shoots and leaves of the tiny, unassuming periwinkle plant.

MIT researchers studying the flowering plant have now figured out how to manipulate those complicated biosynthetic pathways to produce novel compounds, some of which could have pharmacological benefits.

"Plants are really nature's best chemists," says Sarah O'Connor, the Latham Family Career Development Assistant Professor of Chemistry and co-author of a paper on the work in the Journal of the American Chemical Society.

O'Connor and chemistry graduate student Elizabeth McCoy decided to explore the periwinkle plant in part because it is the only plant that produces vinblastine, a drug widely used to treat cancers such as Hodgkin's lymphoma.

The biochemical pathway that produces vinblastine and other alkaloid compounds is long and complicated, usually requiring at least 10 enzymatic steps, which occur in different parts of the periwinkle plant (also known as Catharanthus roseus).

O'Connor and McCoy essentially tricked the plants into producing new compounds by feeding them slightly altered versions of the normal starting materials (tryptamines) for alkaloid synthesis.

"You can make a great number of modifications of simple starting materials, and the plants incorporate those starting materials into the biosynthetic pathway," said O'Connor.

Alkaloids are believed to have a protective function for plants because they are toxic to bacteria and herbivores who try to eat the plants. This theory is bolstered by the fact that the reaction products move closer to the plant surface as they move through the biosynthetic pathway, said McCoy.

Vinblastine, which has been used as a cancer drug since the 1960s, is very difficult to isolate from the periwinkle plant because it is produced in minute quantities (the yield is about 0.002 percent of the plant's weight). However, it would be even more difficult (and expensive) to synthesize vinblastine in the laboratory.

"It's a beautiful and elegant synthesis, but it's not cost-effective, so industry does not currently use synthesis to make vinblastine," said O'Connor.

Other researchers are now running clinical trials for artificial analogues of vinblastine, so it could be beneficial if periwinkle plants could be induced to synthesize those same compounds or new compounds that might be even more effective.

Because it is easier to make modifications to the starting materials than the end product, the researchers' method could produce a diverse array of alkaloids to test for potential drug activity. "You can only make a limited number of modifications to natural products that are already synthesized," O'Connor said.

In their recent paper, the researchers describe 18 new products, but there are many more possibilities. "There's no end to what you could do to modify the starting materials," said McCoy.

Scientists often engineer bacteria and yeast to produce desired compounds, such as antibiotics, but few have tried it with plants, because their biochemistry is so complex.

"Plants are the hardest to work with, so people have avoided looking at plant biosynthetic pathways," O'Connor said.

The research is funded by the Smith Family Medical Foundation, 3M, the Beckman Foundation, the American Cancer Society and the American Chemical Society.

A version of this article appeared in MIT Tech Talk on November 15, 2006 (download PDF).


Topics: Bioengineering and biotechnology, Cancer, Chemistry and chemical engineering, Health sciences and technology

Comments

Back to the top